SEC Company Response from BeOne Medicines Ltd. (ONC, BEIGF) (CIK 0001651308) (ONC) — Jan 29, 2016
BeOne Medicines Ltd. (ONC, BEIGF) (CIK 0001651308)
Date: Jan. 29, 2016 · CIK: 0001651308 · Accession: 0001104659-16-092452
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-207459
Letter
Goldman, Sachs & Co.
200 West Street
New York, New York 10282
Morgan Stanley & Co. LLC
1585 Broadway
New York, New York 10036
Cowen and Company, LLC
599 Lexington Avenue, 27th Floor
New York, NY 10022
January 29, 2016
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Scot Foley
Re: BeiGene, Ltd.
Registration Statement on Form S-1 (File No. 333-207459)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of BeiGene, Ltd. (the “Company”) for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:00 PM, Eastern Time, on February 2, 2016, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective.
Pursuant to Rule 460 under the Act, we, as representatives of the several underwriters, wish to advise you that we have effected the following distribution of the Company’s Preliminary Prospectus dated January 19, 2016:
(i) Dates of distribution: January 19, 2016 through the date hereof
(ii) Number of prospective underwriters to which the preliminary prospectus was furnished: 4
(iii) Number of prospectuses furnished to investors: approximately 4162
(iv) Number of prospectuses distributed to others, including the Company, the Company’s counsel, independent accountants, and underwriters’ counsel: approximately 10
We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
GOLDMAN, SACHS & CO.
Show Raw Text
CORRESP 1 filename1.htm Goldman, Sachs & Co. 200 West Street New York, New York 10282 Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Cowen and Company, LLC 599 Lexington Avenue, 27th Floor New York, NY 10022 January 29, 2016 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Scot Foley Re: BeiGene, Ltd. Registration Statement on Form S-1 (File No. 333-207459) Request for Acceleration of Effective Date Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of BeiGene, Ltd. (the “Company”) for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:00 PM, Eastern Time, on February 2, 2016, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective. Pursuant to Rule 460 under the Act, we, as representatives of the several underwriters, wish to advise you that we have effected the following distribution of the Company’s Preliminary Prospectus dated January 19, 2016: (i) Dates of distribution: January 19, 2016 through the date hereof (ii) Number of prospective underwriters to which the preliminary prospectus was furnished: 4 (iii) Number of prospectuses furnished to investors: approximately 4162 (iv) Number of prospectuses distributed to others, including the Company, the Company’s counsel, independent accountants, and underwriters’ counsel: approximately 10 We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. Very truly yours, GOLDMAN, SACHS & CO. MORGAN STANLEY & CO. LLC COWEN AND COMPANY, LLC Acting severally on behalf of themselves and the several Underwriters GOLDMAN, SACHS & CO. By: /s/ Matt Leavitt Name: Matt Leavitt Title: Managing Director MORGAN STANLEY & CO. LLC By: /s/ David Lederman Name: David Lederman Title: Vice President COWEN AND COMPANY, LLC By: /s/ Grant Miller Name: Grant Miller Title: Managing Director, Head of Equity Capital Markets